Korean J Fam Pract. 2017; 7(6): 844-850  https://doi.org/10.21215/kjfp.2017.7.6.844
Association of Apolipoprotein B with HbA1c in Nondiabetic Adults
Soo-Eun Jang, Woo-Joo Park, Hyun-Ha Kim, Seung-Ryoung Yoo, Jung-Ran Lee, Mi-Kyeong Oh*
Department of Family Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea
Mi-Kyeong Oh
Tel: +82-33-610-3325, Fax: +82-33-641-8130
E-mail: omk@gnah.co.kr
Received: March 7, 2017; Revised: June 30, 2017; Accepted: July 17, 2017; Published online: December 20, 2017.
© Korean Academy of Family Medicine. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background: Apolipoprotein B (ApoB) is associated with atherosclerotic disease and has recently been associated with metabolic syndrome. However, there are no studies examining the correlation between diabetes mellitus (DM) and ApoB in nondiabetic adults. The aim of this study was to evaluate the association between ApoB and glycated hemoglobin (HbA1c) in nondiabetic adults.
Methods: Subjects included 410 individuals (aged >18 years) with a record of a minimum of two medical check-ups at the health promotion center of Gangneung Asan Hospital between February 2014 and October 2016, with no DM and no underlying disease. We investigated the association between serum lipid profile and HbA1c levels and between baseline ApoB levels and changes in HbA1c levels after 1 to 2 years.
Results: High ApoB levels in both sexes were associated with high HbA1c levels. Compared to other lipid profile tests, in men, ApoB correlated with HbA1c, even after adjusting for age and body mass index (BMI) (P<0.05). In women, ApoB correlated with HbA1c (P<0.05), although the association was not statistically significant after adjusting for age and BMI. High baseline levels of ApoB were associated with increases in HbA1c after 1 to 2 years in women (P<0.05). However the association was not statistically significant in men.
Conclusion: ApoB was significantly associated with HbA1c and high ApoB levels at baseline in women were associated with increased HbA1c levels after 1 to 2 years.
Keywords: Apolipoproteins B; Glycated Hemoglobin A; Diabete Mellitus; Dyslipidemias
References
  1. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.
    Pubmed CrossRef
  2. Björntorp P. Abdominal obesity and the metabolic syndrome. Ann Med 1992; 24: 465-8.
    Pubmed CrossRef
  3. Mykkänen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998; 47:793-800.
    Pubmed CrossRef
  4. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94.
    CrossRef
  5. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 151420.
    CrossRef
  6. Liese AD, Mayer-Davis EJ, Tyroler HA, Davis CE, Keil U, Duncan BB, et al. Development of the multiple metabolic syndrome in the ARIC cohort: joint contribution of insulin, BMI, and WHR. Atherosclerosis risk in communities. Ann Epidemiol 1997; 7: 407-16.
    CrossRef
  7. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-97.
    CrossRef
  8. Grundy SM. Cholesterol-lowering clinical trials: a historical perspective. In:Grundy SM, editor. Cholesterol-lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker; 2000. p. 1-44.
    Pubmed
  9. Gadi R, Samaha FF. Dyslipidemia in type 2 diabetes mellitus. Curr Diab Rep 2007; 7: 228-34.
    Pubmed CrossRef
  10. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence. J Intern Med 2006; 259: 493-519.
    Pubmed CrossRef
  11. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361: 777-80.
    CrossRef
  12. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.
    CrossRef
  13. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
    CrossRef
  14. Wägner AM, Pérez A, Zapico E, Ordóñez-Llanos J. Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients. Diabetes Care 2003; 26: 2048-51.
    Pubmed CrossRef
  15. Kim H, Yi S, Son EI, Kim J. Differential effects of left versus right mesial temporal lobe epilepsy on Wechsler intelligence factors. Neuropsychology 2003;17: 556-65.
    Pubmed CrossRef
  16. Bae Y, Rhew JY, Cho IJ, Ryu MH, Seo JP, Gill GC, et al. A study of plasma apolipoprotein A-1 and apolipoprotein B levels in patients with coronary artery disease. Korean Circ J 1995; 25: 967-74.
    CrossRef
  17. Park HS, Kim YS, Min WK, Lee CW, Park SW, Park SJ. A case-control study on the risk factors for coronary artery disease among Korean. Korean Circ J 1998; 28: 849-62.
    CrossRef
  18. Hwang ST, Kim BJ, Kim ER, Shin HS, Sung KC, Kim BS, et al. Concordance/discordance between apolipoprotein B levels and the cholesterol indexes. Korean Circ J 2005; 35: 436-42.
    CrossRef
  19. Sierra-Johnson J, Somers VK, Kuniyoshi FH, Garza CA, Isley WL, Gami AS, et al. Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am J Cardiol 2006; 98: 1369-73.
    Pubmed CrossRef
  20. Alfadda AA, Al-Daghri NM, Malabu UH. Apolipoprotein B/apolipoprotein A-I ratio in relation to various definitions of metabolic syndrome among Saudi patients with type 2 diabetes mellitus. Saudi Med J 2008; 29: 821-5.
    Pubmed
  21. Hwang ST, Sung KC, Kim BJ, Kim BS, Kang JH, Lee MH, et al. Insulin resistance and apolipoprotein B as a metabolic syndrome risk factor in normal glucose tolerance. Korean J Med 2004; 66: 156-66.
  22. Grundy SM. Approach to lipoprotein management in 2001 National Cholesterol Guidelines. Am J Cardiol 2002; 90: 11i-21i.
    CrossRef
  23. Jiang R, Schulze MB, Li T, Rifai N, Stampfer MJ, Rimm EB, et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 2004; 27: 1991-7.
    Pubmed CrossRef
  24. Taghibiglou C, Rashid-Kolvear F, Van Iderstine SC, Le-Tien H, Fantus IG, Lewis GF, et al. Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance. J Biol Chem 2002; 277: 793-803.
    Pubmed CrossRef
  25. Relimpio F, Losada F, Pumar A, Mangas MA, Morales F, Astorga R. Relationships of apolipoprotein B(100) with the metabolic syndrome in Type 2 diabetes mellitus. Diabetes Res Clin Pract 2002; 57: 199-207.
    CrossRef
  26. Kang YH, Yi DW. Significance of ApoB and ApoB/A-I as a marker of metabolic syndrome in type 2 diabetes. Journal of Pusan National University Hospital 2011; 29: 24-35.
  27. Watts GF, Chan DC, Ooi EM, Nestel PJ, Beilin LJ, Barrett PH. Fish oils, phytosterols and weight loss in the regulation of lipoprotein transport in the metabolic syndrome: lessons from stable isotope tracer studies. Clin Exp Pharmacol Physiol 2006; 33: 877-82.
    Pubmed CrossRef
  28. Matthan NR, Welty FK, Barrett PH, Harausz C, Dolnikowski GG, Parks JS, et al. Dietary hydrogenated fat increases high-density lipoprotein apoA-I catabolism and decreases low-density lipoprotein apoB-100 catabolism in hypercholesterolemic women. Arterioscler Thromb Vasc Biol 2004; 24:1092-7.
    Pubmed CrossRef
  29. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ 1989;298: 784-8.
    Pubmed KoreaMed CrossRef
  30. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994; 106: 241-53.
    CrossRef


This Article

e-submission

Archives